Seelos Therapeutics, Inc.
SEEL · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.39 | 0.13 | -0.56 |
| FCF Yield | -11.36% | -2.15% | -0.38% | -0.18% |
| EV / EBITDA | 10.54 | -86.99 | -96.03 | 303.36 |
| Quality | ||||
| ROIC | 17.51% | 30.33% | 41.55% | 93.66% |
| Gross Margin | -100.80% | 97.41% | 97.70% | 96.55% |
| Cash Conversion Ratio | -0.57 | 1.74 | 0.35 | -0.55 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,262,754.03% | 1,254,337.56% | 1,301,082.36% | -52.32% |
| Free Cash Flow Growth | 79.06% | -142.91% | 66.76% | 2.63% |
| Safety | ||||
| Net Debt / EBITDA | 5.64 | -4.80 | -2.07 | 1.36 |
| Interest Coverage | -136.48 | -263.26 | -421.63 | -300.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,824.85 | -91,457.53 | -98,312.84 | -38,458.15 |